Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish speaking~* women aged 15-45 years of age~* Currently using the ENG-implant for at least 1 month and use proven on exam (palpation of implant at screening visit)~* Willing to continue using the implant for at least 6 months~* \>7 days of continuous bleeding/spotting, or 2 or more episodes of bleeding/spotting in the last 30 days.~* Cellphone that is able to receive and respond to a daily text or email message .~Exclusion Criteria:~* Postpartum within six months~* post-abortion within six weeks~* currently pregnant~* currently breast-feeding~* undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant~* bleeding dyscrasia~* anticoagulation use~* active cervicitis~* allergy to tamoxifen~* history of venous thromboembolism~* current or past breast or uterine malignancy~* use of medication contraindicated with tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital).

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Tamoxifen (Type: EXPERIMENTAL): Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding

Based on this trial design, predict the completion outcome and termination type (if applicable).